Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes

Alice J Walmesley, Jehad Zweiri, Stephen E Christmas, Alastair J M Watson

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) is overexpressed in colon tumors. Its main product is the immunosuppressive prostaglandin PGE2 that aids tumor immune escape. In this study, we analyzed mechanisms of action of the COX-2 inhibitor rofecoxib on the immune response to colorectal cancer in an animal model. The murine colorectal cancer cell line MC26, and splenocytes from BALB/c mice immune to irradiated MC26 cells, were incubated with rofecoxib or PGE2. In MC26 cells, 100 nM rofecoxib caused a complete abrogation of PGE2 production and inhibited cell proliferation. Splenocytes from tumor immune mice showed a 300% (P
Original languageEnglish
Pages (from-to)614-623
Number of pages10
JournalJournal of Immunotherapy
Volume30
Issue number6
DOIs
Publication statusPublished - Sep 2007

Keywords

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Chemokines
  • Colorectal Neoplasms
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Dinoprostone
  • Female
  • Gene Expression
  • Lactones
  • Mice
  • Mice, Inbred BALB C
  • Monocytes
  • Spleen
  • Sulfones

Cite this